巴瑞替尼联合窄谱UV-B治疗成人活动性白癜风:随机临床试验
这项多中心、双盲、非比较性随机临床试验纳入49例广泛活动性非节段性白癜风成人患者,按3:1随机分配至巴瑞替尼4mg/日组或安慰剂组,前12周单药治疗,第12至36周联合窄谱UV-B每周两次。主要终点第36周总VASI平均变化百分比在巴瑞替尼组为-44.8%(95%CI -58.4%至-31.3%),未显著大于预设的42.9%复色阈值;
要点
- 巴瑞替尼联合窄谱UV-B在第36周总VASI平均变化为-44.8%,未达预设42.9%阈值。
- 巴瑞替尼组疾病活动度和生活质量改善更明显,不良事件数无显著差异。
核心结论
- 巴瑞替尼联合窄谱UV-B在广泛活动性白癜风治疗中显示疗效,但主要终点未达到预设的显著优于42.9%复色阈值。
研究设计与样本
- 学术性、多中心、双盲、非比较性随机临床试验,在4个皮肤科开展,2021年7月至2023年4月纳入49例广泛活动性非节段性白癜风成人患者。
- 患者按3:1随机分配至巴瑞替尼4mg/日组(37例)或安慰剂组(12例),前12周单药治疗,第12至36周联合窄谱UV-B每周两次。
- 主要终点为巴瑞替尼组第36周总VASI评分较基线的平均变化百分比,预设目标为显著大于42.9%的复色表面积阈值。
主要发现
- 第36周总VASI平均变化:巴瑞替尼组-44.8%(95%CI -58.4%至-31.3%),安慰剂组-9.2%(95%CI -27.7%至24.7%)。
- 巴瑞替尼组总VASI变化未显著大于42.9%的复色阈值。
- 巴瑞替尼组疾病活动度和生活质量改善优于安慰剂组,不良事件数无显著差异。
关键数值与推荐
- 主要终点阈值:总VASI变化需显著大于42.9%(既往窄谱UV-B单药治疗的复色表面积阈值)。
- 巴瑞替尼组第36周总VASI平均变化-44.8%(95%CI -58.4%至-31.3%)。
- 安慰剂组第36周总VASI平均变化-9.2%(95%CI -27.7%至24.7%)。
临床怎么用
- 巴瑞替尼联合窄谱UV-B可作为广泛活动性白癜风患者的潜在治疗选择,但需注意主要终点未达预设阈值。
- 治疗前12周巴瑞替尼单药,随后联合窄谱UV-B每周两次,共36周方案在研究中显示可改善疾病活动度和生活质量。
局限性
- 研究为非比较性设计,安慰剂组仅作为校准组,样本量较小(共49例)。
- 主要终点未达到预设的显著优于42.9%阈值,疗效结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vitiligo is a chronic autoimmune disorder leading to skin depigmentation and reduced quality of life (QOL). Patients with extensive and very active disease are the most difficult to treat. OBJECTIVE: To assess the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo. DESIGN, SETTING, AND PARTICIPANTS: This academic, multicenter, double-blind, noncomparative randomized clinical trial was conducted at 4 dermatology departments between July 2021 and April 2023 and included adult patients with extensive and active nonsegmental vitiligo. The study was designed to evaluate the effect of baricitinib plus narrowband UV-B based solely on the results from this experimental group. The placebo group was used as a calibration group. Data were analyzed from August to November 2023. INTERVENTIONS: Participants were randomized 3:1 to baricitinib, 4 mg per day, or placebo for 36 weeks alone for the first 12 weeks and then in combination with narrowband UV-B twice a week from weeks 12 to 36. MAIN OUTCOMES AND MEASURES: The primary outcome was mean percentage change in total Vitiligo Area Scoring Index (VASI) score from baseline to week 36 (baricitinib group). The prespecified aim of the study was to show that the reduction in the baricitinib plus narrowband UV-B was significantly greater than 42.9%, a repigmented surface threshold previously observed in patients treated with narrowband UV-B alone. Adverse events and secondary outcomes of change in disease activity and QOL were assessed. Post hoc analyses were additionally performed. RESULTS: Of 49 included patients, 35 (71%) were female, and the median (IQR) age was 49.9 (38.4-59.8) years. A total of 37 patients were randomized to the baricitinib group and 12 to the placebo group. The mean change in total VASI at week 36 was -44.8% (95% CI, -58.4% to -31.3%) for the baricitinib group and -9.2% (95% CI, -27.7% to 24.7%) for the placebo group. This was not significantly greater than the sufficient repigmented surface threshold of 42.9%. Post hoc analyses showed a significant difference at week 36 for total VASI score in the baricitinib plus narrowband UV-B group compared with placebo plus narrowband UV-B (-44.8% vs -9.2%, respectively; P = .02). There was a greater improvement in disease activity and QOL in the baricitinib group vs placebo group and no significant difference in the number of adverse events. CONCLUSIONS AND RELEVANCE: This proof-of-concept randomized clinical trial confirmed the efficacy of baricitinib combined with narrowband UV-B in the treatment of patients with extensive and active vitiligo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04822584.
引用
- Seneschal J, Guyon M, Merhi R, et al. Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 39841460. doi:10.1001/jamadermatol.2024.5737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。